Nanosensors and Nanomodulators in Cancer Therapies

Dear Colleagues,

Diagnosing and training cancer with nanotechnology-based approaches is tremendously promising, as it can result in lower side effects and personalized interventions that lead to long-term disease remission. However, the effectiveness of nanotechnology-based approaches has not been consistent. A key variability driver in therapeutic responses is a current lack of technologies to design and implement personalized treatments.

The intersection of nanoscience with cancer therapies opens a world of new opportunities for personalized interventions. An incomplete list of such opportunities includes (1) ultrasensitive nanosensors detecting minute amounts of a biomarker, which could, in turn, enable the detection of multiple biomarkers out of a limited biopsy sample; (2) nanoparticles helping make a tumor visible to the physician, thus enhancing the possibility of successful surgical resection; (3) novel nanomaterials implanted in vivo to sequester biomarkers and/or cancer-relevant ligands to guide the synthesis of personalized treatments;  (4) nanoparticles engineered in various architectures to help visualize therapy response or serve as patient-specific treatments, e.g., adeno-associated viruses, lentiviruses, lipid nanoparticles, and extracellular vesicles.

The current Special Issue emphasizes research at the intersection of nanosensing (devices) and nanomodulation (nanoparticles) for all aspects of cancer therapy, including diagnostic biomarker detection, validation of tumor targeting, and therapeutic response monitoring. It is highly encouraged that submitted manuscripts include a candid discussion of how the proposed technologies or methods could address current weaknesses in established interventions and describe the critical future milestones that would need to be attained to enable their successful translation to the clinic.

Prof. Dr. Georgios Alexandrakis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.